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ABSTRACT p34 kinase, the product of the CDC2 gene, is
a cell-cycle regulated protein kinase that is most active during
mitosis. In HeLa cells, p34 kinase has previously been shown
to exist in both a low- and a high-molecular-mass form, the
latter of which is only found in cells in the G2/M phase of the
cell cycle and contains a 62-kDa subunit. Here we show that
although each form ofthe kinase phosphorylates casein in vitro,
only the high-molecular-mass form uses histone H1 as sub-
strate. The high-molecular-mass form of p34 kinase from
nocodazole-treated HeLa cells was purified 6700-fold. The
apparent molecular mass of the mitotic CDC2-encoded protein
kinase complex was 220 kDa. The purified enzyme phospho-
rylated not only its endogenous 62-kDa subunit but also
phosphorylated histone H1 with a Km of 3 ,uM and used ATP
40 times more efficiently than GTP (Km 54 juM and 2 mM,
respectively). The enzyme activity was unaffected by cAMP,
calcium/calmodulin, or by the heat-stable inhibitor of cAMP-
dependent protein kinase. These characteristics are typical of
growth-associated histone H1 kinase from different organisms.
These results suggest that CDC2 protein may be activated as an
M-phase-specific protein kinase in part by its association with
the p62 subunit.
Several genes coding for putative protein kinases that are
involved in the control of mitotic initiation have been isolated
in fission yeast, namely cdc2+ (1, 2), wee]' (3), and nimJ+
(4). Among these, cdc2+ has been the object of extensive
genetic and biochemical analysis because of its dual regula-
tory role, in G1 before the initiation ofDNA synthesis and in
G2 before mitosis (1, 5). cdc2+ is the homolog of the CDC28
"start" gene of budding yeast (6) and encodes a 34-kDa
protein with kinase activity (2). This protein has been shown
to be associated with the 13-kDa product of the sucl+ gene
of fission yeast (7) and also with the 63-kDa yeast cyclin,
which is encoded by the cdc13+ gene (R. Booher, C. Alfa, J.
Hyams, and D.B., unpublished data). A CDC2 protein ho-
molog has also been identified in human cells (9) in associ-
ation with the 13-kDa SUC1 protein homolog. The human
CDC2 gene has been isolated by complementation of a yeast
cdc2 temperature-sensitive mutant (10).
Entry of interphase cells into mitosis is regulated by the
M-phase-promoting factor (MPF), a non-species-specific mi-
totic inducer that was first described in amphibian oocytes
(11, 12). The cdc2 protein kinase (p34) has been shown to be
a component of the frog MPF (13, 14) in addition to being a
component of the M-phase-specific histone H1 kinase of
starfish oocytes (15, 16).
Mammalian cells have a CDC2 protein kinase (9), a
"growth-associated" histone H1 kinase (17), and assayable
MPF activity during mitosis (18). However, none of these
activities have yet been directly interconnected in mammalian
cells. The properties ofp34 kinase in HeLa cells are consistent
with its involvement in initiating mitosis. The protein kinase is
activated in a series of steps during cell-cycle progression and
is maximally active during mitosis (19). Activation involves
phosphorylation of p34 kinase and association with a 62-kDa
protein, which also acts as substrate of p34 kinase in vitro. A
possible regulatory role of the phosphotyrosine content ofp34
kinase on its mitotic activity has also been recently suggested
(20). In this paper we have characterized the CDC2 mitotic
complex and show that it is a high-affinity histone H1 kinase.
MATERIALS AND METHODS
Cell Culture and Preparation of Extracts. For the purifica-
tion of the mitotic form ofp34 kinase, HeLa cells were grown
in suspension at 370C in Joklik-modified minimal essential
medium supplemented with 5% calf serum (GIBCO) to a final
density of 5 x 105 cells per ml. Nocodazole (Jannsen Phar-
maceutica) was then added to a final concentration of 1
,ug/ml. Cells were harvested after 4 hr of drug treatment and
washed with ice-cold phosphate-buffered saline. Cells ob-
tained from 32 liters of culture were lysed in 100 ml of
hypotonic buffer (10 mM sodium phosphate, pH 7.0/10 mM
NaF/5 mM MgCl2/1 mM EDTA/10 mM B-glycerophos-
phate) using a Dounce homogenizer, in the presence of a
mixture of protease inhibitors (19). The cell lysate was
centrifuged at 100,000 x g for 45 min, and the supernatant
was collected. For the Superose 12 fractionation experi-
ments, extract preparation and chromatographic procedure
were done exactly as described (19).
Kinase Assays. Anti-p34 kinase immunocomplexes and
p13-Sepharose precipitates, prepared as described previ-
ously (16, 19), or purified enzyme were preincubated for 1.5
min at 30°C in a final volume of 45 ,ul of buffer K (50 mM
Tris HCI, pH 8.0/10 mM MgC12/1 mM dithiothreitol. Five
microliters of ATP was then added (to a final concentration
of 5 ,uM and 5 ,uCi per reaction; 1 Ci = 37 GBq). The reaction
mixtures were incubated for 10 min after adding ATP. Calf
histone H1 (Boehringer Mannheim) or dephosphorylated
casein (Sigma) were included at a final concentration of 50
,ug/ml and 1 mg/ml, respectively. The reaction was stopped
by adding 30 p.l of electrophoresis sample buffer (21). Sam-
ples were then analyzed by SDS/PAGE (7.5-15% gels).
Subsequently, the proteins were transferred to 0.1 pum nitro-
cellulose filters, followed by autoradiography. To estimate
the incorporation of 32p into protein, a fraction of the stopped
reaction was trichloroacetic acid-precipitated and counted.
Purification of the High-Molecular-Mass Form of the CDC2
Kinase. The assay used to detect the high-molecular-mass
CDC2 kinase complex during the purification procedure
made use of the autophosphorylation of the p62 subunit in
p13-Sepharose precipitates. The protocol for protein purifi-
cation was as follows: 25-45% (NH4)2SO4 precipitate was
obtained from the 100,000 x g supernatant of 32 liters ofHeLa
Abbreviation: MPF, M-phase-promoting factor.
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cells and resuspended in 100 ml of buffer 1A (50 mM Tris HCl,
pH 7.0/5 mM MgCl2/1 mM EDTA/1 mM dithiothreitol/10mM
3-glycerophosphate). The protein solution was dialyzed for 4 hr
against 1-2 liters of buffer 1A, and the conductivity of the
solution was adjusted to that of buffer 1B (buffer 1A contained
80 mM NaCI). The protein solution was loaded onto a 10-ml
DE-52 column (Whatman) equilibrated with buffer 1B. The
flow-through and a 10-ml wash were pooled and concentrated
down to 5 ml, followed by overnight dialysis against 1000 ml of
buffer 2 (50 mM Hepes, pH 7.0/5 mM MgCl2/1 mM EDTA/1
mM dithiothreitol/10o glycerol/100 mM NaCl). The sample
was then loaded onto a Mono S 10/10 column (Pharmacia)
equilibrated in the same buffer, and protein was eluted with 125
ml of linear NaCl gradient (from 100 to 500 mM). The fractions
with kinase activity were pooled and diluted with buffer 1A until
they reached the same conductivity value of buffer 1B. The
sample was then loaded onto a 5-mI casein-Sepharose column
(5 mg of casein per ml) equilibrated in buffer 1B and eluted with
a 70-ml NaCl gradient (80-500 mM gradient). One-milliliter
fractions were collected. Active fractions were pooled and
diluted with buffer 1A to the conductivity value ofbuffer 1B and
loaded onto a Mono Q 5/5 column (Pharmacia). A 20-ml NaCl
gradient was applied (from 80 to 500 mM), and 0.4-ml fractions
were collected. The fractions with activity were pooled and
concentrated to 0.5 ml, which was then loaded onto a Superose
12 column (Pharmacia) equilibrated with buffer S, and 0.25-ml
fractions were collected. Protein concentration of the different
fractions was determined using the colorimetric assay described
by Bradford (22) by using IgG (Bio-Rad) as standard. In addition
absorbance at 280 nm was used to estimate protein concentra-
tions in later steps of purification.
Calculation of Kinetic Parameters. Characterization of the
CDC2 kinase activity was done by incubating 5 ttl of the
Mono Q pool for 3 min as described under kinase assays. All
reagents used were obtained from Sigma. [y-32P]ATP (3000
Ci/mmol) and [y-32PJGTP (650 Ci/mmol) were obtained from
NEN and ICN, respectively.
RESULTS
Histone H1 Kinase Activity of CDC2 Protein Complex. We
have previously found that in exponentially growing HeLa
cells, p34 kinase exists in at least two different forms,
depending on the state of association with other cellular
proteins (19). The two forms could be dissociated by gel-
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filtration chromatography into fractions with apparent mo-
lecular masses of =30 and 200 kDa. The high-molecular-mass
form, which increases in abundance during progression
through interphase, contains a 62-kDa subunit that acts as a
substrate of the CDC2 kinase in vitro. Activity with respect
to p62 as substrate is enhanced in cells arrested in mitosis by
nocodazole. With the same chromatographic procedure used
previously (19) we have fractionated 100,000 x g superna-
tants of HeLa cells with or without prior exposure to no-
codazole. A portion of each fraction was precipitated with
p13-Sepharose (Fig. 1), a reagent that has been used to assay
cdc2 kinase activity in starfish and clam oocytes (16, 23). The
precipitates were incubated with [y-32P]ATP and either
casein (Fig. 1 Upper) or histone H1 (Fig. 1 Lower).
In common with previous experiments in which anti-p34
kinase serum was used to precipitate the protein kinase from
column fractions (19), the casein kinase activity of CDC2
protein resolved into two distinct peaks of very different
molecular mobility. p62 is only present in the high-molecular
fraction (Fig. 1; ref. 19). Only the higher-molecular-mass form
was activated after exposure of cells to nocodazole. Also the
preference of the kinase for each of the two forms of casein (a
and ,B) was different in the two fractions. This apparent change
in specificity was much more marked using histone H1 as
substrate. Histone H1 was phosphorylated exclusively by the
high-molecular-mass protein kinase complex, and the histone
H1 kinase activity was enhanced by exposure to nocodazole
(Fig. 1 Lower). Also histone H1 conspicuously competed with
phosphorylation of p62 in the immune complex, whereas
casein did not. Precisely the same observations were made
using anti-p34 kinase antibodies to immunoprecipitate and
assay the column fractions (data not shown).
Purification of CDC2 Protein Kinase Complex. Purification
of the mitotic complex was followed by analyzing the phos-
phorylation of p62 in p13-Sepharose precipitates of column
fractions. The design of the strategy is 3-fold. (i) p13-
Sepharose is used to assay p34 kinase-dependent kinase
activity because it displays the same specificity as anti-p34
antibodies (Fig. 1; ref. 19). Use of this reagent both acceler-
ates and simplifies the assay procedure compared with immu-
noprecipitation. (ii) By assaying autophosphorylation of p62,
only the high-molecular-mass CDC2 complex is purified. (iii)
To enrich for the activity of the p34 kinase mitotic complex
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FIG. 1. Changes in substrate specificity of p34 protein. Protein extract (1.5 mg) from HeLa cells treated for 4 hr with nocodazole at 1 ,ug/ml(Right) or equivalent amount of protein from control cells (Left) were fractionated by gel filtration on a Superose 12 column. p13-Sepharose
precipitates of each fraction were assayed for kinase activity using either casein at 1 mg/ml or histone H1 at 50 pgg/ml as substrates (Upper and
Lower, respectively) in the presence of (y-32P]ATP. The elution positions of catalase (CAT), cytochrome c (CYT), and ovalbumin (OVA) from
the Superose 12 column are indicated. A and A represent the elution position of the high- and low-molecular-mass forms of p34, respectively.
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FIG. 2. High-molecular-mass complex contains only a minor
fraction ofp34 kinase. (A) Anti-p34 immunoprecipitates ofequivalent
volumes of HeLa 100,000 x g supernatant (S100) and (NH4)2SO4
fractions were prepared without and with antigenic peptide (- and +
pep) and assayed for kinase activity in the absence of externally
added substrates. Molecular mass of standard proteins is given in
kDa. (B) Immunoblot of equivalent volumes of 100,000 x g super-
natant and relevant (NH4)2SO4 fractions using 1:1000 dilution of
anti-p34 immune serum. Thirty nanograms of bacterial (bact.) p34
kinase was used as marker. sup, Supernatant; pel, pellet.
in the starting material, HeLa cells were incubated for 4 hr
with nocodazole before harvesting.
The first step of purification was ammonium sulfate pre-
cipitation of the 100,000 x g supernatant of the cell extract.
The CDC2 protein kinase activity precipitated 25-45% salt
saturation (Fig. 2A), but the great majority of p34 kinase,
detected by immunoblotting (Fig. 2B), remained soluble at
45% salt saturation.
After ammonium sulfate precipitation, the CDC2 protein
kinase complex was recovered in the flow-through and wash
of the DE-52 column equilibrated with a buffer at pH 7.0
containing 80 mM NaCl. Most proteins were retained by the
column under these conditions (Table 1). The active material
was loaded onto a Mono S column to which it bound in low salt
and could be eluted at 260 mM NaCl (Fig. 3A). The next step
of purification took advantage of the ability of p34 kinase to
bind to a casein-agarose matrix (20), from which it eluted at
250mM NaCl (Fig. 3B). The pool ofmost active fractions from
casein-agarose chromatography was diluted and applied to a
Mono Q column, from which the activity eluted at 125 mM
NaCl (data not shown). Although each chromatographic step
lost protein kinase activity (Table 1), this loss was not due to
inherent instability of the enzyme, which could be stored for
weeks at 4°C without appreciable inactivation.
After the Mono Q step, 3600-fold purification of the kinase
activity had been acnieved. At this stage the enzyme is
substantially pure as a protein kinase, assayed directly as a
p62, casein, or histone H1 kinase, without prior immuno-
precipitation or incubation with p13-Sepharose (Fig. 4). At
6700-fold purification, achieved by Superose 12 chromatog-
raphy of the Mono Q fractions, silver staining of column
fractions resolved by SDS/PAGE revealed the p34 and p62
polypeptides (data not shown) but did not allow an unequiv-
ocal determination of the total subunit composition of the
kinase due to the presence of less abundant, but detectable,
high-molecular-mass polypeptides. This has been a problem
in other efforts to purify complexes containing CDC2 protein
(16, 24). We could not unequivocally establish whether the
p13 subunit was present in the most purified fractions due to
the lack of crossreactivity of the anti-p13 serum with the
mammalian p13 immobilized in nitrocellulose and also be-
cause of the poor reactivity of this protein in silver staining.
The apparent molecular mass of the CDC2 kinase complex
was 220 kDa, as determined by gel filtration (Fig. 3C).
Kinetic characterization of the purified (post-mono Q)
CDC2 protein kinase complex was performed by following
the activity of the enzyme in solution. Incorporation of 32P
into histone H1 was linear during the first 3 min of reaction
at 30°C (data not shown). Table 2 summarizes several kinetic
properties of the kinase. Km values for ATP (54 ,M), GTP (2
mM), and histone H1 (3 A.M) were determined. No effect on
the kinase activity was seen upon incubation of the enzyme
with 10,M cAMP, 0.6 ,.M heat-stable protein kinase A
inhibitor, or 1 ,uM bovine testis calmodulin. Purified p13 was
also added to kinase reactions at concentrations up to 20 ,uM.
No inhibition of the enzyme was noted during the standard
10-min reactions and, indeed, at prolonged intervals of incu-
bation there was a slight stabilization of enzymatic activity
(data not shown). Optimal activity for the phosphorylation of
histone H1 was achieved in a wide pH range between 8 and
9 at a MgCl2 concentration of 10 mM, which could be
substituted by MnCl2. No ability of the kinase to phospho-
rylate histone H3 was found.
DISCUSSION
The most striking observations of the present experiments
are 2-fold. First, p13-Sepharose can be used interchangeably
with anti-p34 serum as a reagent to assay both the complexed
and low-molecular-mass forms ofhuman CDC2 protein, even
though much of the p34 kinase is complexed with p13 in vivo
(9, 19). This observation and a similar one with respect to the
histone H1 kinase activity of starfish (16) are surprising
because exogenous p13 inhibits frog MPF activity in a
cell-free assay at concentrations as low as 2 ,uM (20). In our
experiments, p13 at 20,uM did not inhibit histone H1 kinase
activity; these observations indicate that p13 inhibits MPF
activity by a mechanism other than inhibition of the catalytic
activity of CDC2 protein.
Second, p34 is clearly quite inactive as a histone H1 kinase
until it becomes associated with the p62 subunit, even though
the unassociated fraction acts as a casein kinase. Several
explanations may be invoked for this observation: (i) p62
might allosterically alter the properties of p34 kinase, such
that histone H1 becomes available as a substrate. (ii) Alter-
Table 1. Purification of the high-molecular-mass form of p34 kinase from HeLa cells
Total Total Specific
protein, activity, Recovery, activity, Purification,
Step mg cpm x 10-3 % cpm/mg X 10-3 -fold
Supernatant (100,000 x g) 1333 8055 6
Ammonium sulfate 350 5140 64 15 2.5
DE-52 56 5000 62 90 15
Mono S 10/10 4 2432 30 608 100
Casein-agarose 0.15 950 11.8 6,100 1016
Mono Q 5/5 0.02 520 6.5 22,000 3600
Superose 12 10/30 0.008 320 4 40,000 6666
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FIG. 3. Chromatography of CDC2 protein kinase complex. (A) Mono S chromatography of DE-52 eluate. Flow-through and wash of the
DE-52 column were pooled and loaded onto a Mono S column and the bound proteins were eluted with 125-ml NaCl gradient (thin line).
Absorbance at 280 nm represents the protein profile (thick line). Migration of the kinase activity was followed by 32p incorporation into p62
(split line). (B) Chromatography of Mono S pool on casein-agarose: fractions 33-40 from the Mono S chromatography were pooled and diluted
to be loaded onto a 5-ml casein-agarose column. The bound proteins were eluted with 70 ml of NaCl gradient. The same symbols as in A were
used to represent the salt gradient, the protein, and the activity profile. (C) Superose 6 chromatography of Mono Q pool. Fractions containing
activity from the Mono Q column were pooled and concentrated to 0.5 ml before being loaded onto a Superose 6 column. Split lines show the
migration of the kinase activity, and the inset graphically represents the elution volumes (VE) of apoferritin, catalase, bovine serum albumin
(BSA), and the p34 kinase complex in relation to the molecular weights of the standards.
natively, complex formation with p62 might facilitate a sec-
ondary event, such as a phosphorylation of p34 kinase at a
particular site, which alters its substrate specificity. (iii) An
explanation that is not formally excluded by our experiments
is that p34 kinase is not the catalytic subunit ofthe histone Hi
kinase, but rather some other CDC2-associated protein pres-
ent in the mitotic complex.
We think that p62 itself is probably not a protein kinase but
rather a mitotic cyclin. In fission yeast, a 63-kDa cdc2
protein-associated endogenous substrate is the product of
cdcJ3+ (8), which is homologous to cyclins of multicellular
organisms (25). Furthermore, this complex shows a histone
Hi kinase activity in vitro of which p34 kinase has been
shown to be the catalytic subunit. The cdc2/cdc13 complex
Proc. Natl. Acad. Sci. USA 86 (1989) 4365
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exhibits thermolabile histone H1 kinase activity in extracts
prepared from temperature-sensitive cdc2 mutants (R.
Booher, C. Alfa, J. Hyams, and D.B., unpublished data).
Thus, it is likely that in yeast and presumably also in HeLa
cells CDC2 protein is the catalytic subunit of the p34/p62
histone H1 kinase. The role of the cyclin appears, at least in
part, to confer on the CDC2 protein kinase "M-phase spec-
ificity." Degradation of the cyclin at the metaphase/
anaphase transition would cause loss of such specificity and,
thus, loss of MPF activity (23).
The properties of the histone H1 kinase described here are
similar to those of the "growth-associated" histone H1 kinase
partially purified from other mammalian cell types in addition
to representatives of other phyla (26, 27). This kinase activity
has been found in actively proliferating cells. Furthermore,
each of these kinase activities is independent of cAMP, Ca2+,
or calmodulin (28, 29) and has similar Km values for histone H1
(29, 30). The mitotic complex characterized here uses ATP as
a phosphoryl donor with a Km similar to that reported for
Chinese hamster fibroblasts (29) and the starfish histone H1
kinase (30). On the other hand, only the starfish histone H1
kinase and the H1 kinase reported here use GTP, but with very
different Km values (10 ,uM and 2 mM, respectively).
Phosphorylation of histone H1 has been repeatedly postu-
lated but never proven to have a causal role in chromatin
condensation and initiation of mitosis (8, 31). The protein
kinase purified in this study may be used to investigate the
significance of histone phosphorylation in vitro and also to
find other potentially more important mitotic substrates of
the kinase.
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Table 2. Km and IC50 for different compounds
Compound Km IC50
ATP 54 ,uM
GTP 2 mM
Histone H1 3 ,uM
,3-Glycerophosphate 40 mM
NaCI 250 mM
PKI No effect to 0.6 ,uM
cAMP No effect to 10 ,uM
Calmodulin* No effect to 1 ,uM
p13 No effect to 20 ,uM
IC50 was calculated in the presence of6 ,uM histone H1 and 200 ,uM
ATP. PKI, heat-stable inhibitor of the cAMP-dependent protein
kinase.
*Calmodulin was measured in the presence of 1 mM CaCl2.
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FIG. 4. Kinase activity of
CDC2 protein kinase complex.
(A) Ten-microliter aliquots from
the Mono Q fractions were di-
rectly assayed for kinase activ-
ity by addition of [)y-32P]ATP. (B
and C) Casein at 1 mg/ml and
histone H1 at 50 ,ug/ml, respec-
tively, were added as sub-
strates. Autoradiogram in A rep-
resents a 4-hr exposure of the
blotted proteins, whereas B and
C correspond to 10-min expo-
sures.
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